<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>6502</number>
    <updateDate>2019-11-15T21:18:14Z</updateDate>
    <updateDateIncludingText>2019-11-15T21:18:14Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <originChamberCode>H</originChamberCode>
    <type>HR</type>
    <introducedDate>2012-09-21</introducedDate>
    <congress>112</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. BILBRAY:H.R. 6502.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, To regulate Commerce with foreignNations, and among the several States, and with the IndianTribes; Congress has the authority under this section toregulate commerce and FDA products.[Page H6277]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2012-09-26T14:03:53Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2012-09-21T13:03:20Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2012-09-26</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2012-09-21</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2012-09-21</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2012-09-21</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>B000461</bioguideId>
        <fullName>Rep. Bilbray, Brian P. [R-CA-50]</fullName>
        <firstName>BRIAN</firstName>
        <lastName>BILBRAY</lastName>
        <party>R</party>
        <state>CA</state>
        <middleName>P.</middleName>
        <district>50</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>M000087</bioguideId>
        <fullName>Rep. Maloney, Carolyn B. [D-NY-14]</fullName>
        <firstName>CAROLYN</firstName>
        <lastName>MALONEY</lastName>
        <party>D</party>
        <state>NY</state>
        <middleName>B.</middleName>
        <district>14</district>
        <sponsorshipDate>2012-09-21</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>D000216</bioguideId>
        <fullName>Rep. DeLauro, Rosa L. [D-CT-3]</fullName>
        <firstName>ROSA</firstName>
        <lastName>DELAURO</lastName>
        <party>D</party>
        <state>CT</state>
        <district>3</district>
        <sponsorshipDate>2012-09-21</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Advisory bodies</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug therapy</name>
        </item>
        <item>
          <name>Food and Drug Administration (FDA)</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health information and medical records</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Medical research</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2012-09-21</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2012-11-29T20:15:48Z</updateDate>
        <text><![CDATA[ <p>Life-Threatening Diseases Compassion through Combination Therapy Act of 2012 - Amends the Federal Food, Drug, and Cosmetic Act to authorize the Secretary of Health and Human Services (HHS) to designate a combination of drugs as a significant drug combination if such combination: (1) includes two or more drugs or biological products that, when used in combination, offer the potential to significantly advance treatment for a serious or life-threatening disease and, in combination, meet the criteria for co-development of drug combinations in Food and Drug Administration (FDA) guidance; and (2) includes at least two drugs that are not approved.</p> <p>Requires the Secretary to develop, publish, and revise annually a list of combinations of two or more drugs designated as significant drug combinations.</p> <p>Extends the market exclusivity for a drug by six months if it is designated as a significant drug combination before it is approved as a new drug.</p> <p>Requires the Secretary to review and take action on a drug in a significant drug combination designated under this Act within six months after receiving an application for approval of a new drug application or licensure of a biosimilar biological product.</p> <p>Requires the Secretary, at the request of the sponsor of a drug, to expedite development and review for designated drug combinations.</p> <p>Requires the Secretary to establish an interagency task force to encourage the co-development of drugs in significant drug combinations. Requires the task force to develop, revise in response to public comments, and update annually a list of types of drug combinations it recommends that the Secretary designate as significant drug combinations.</p> <p>Directs the Secretary to study the impact of the extension of market exclusivity under this Act.</p>]]></text>
      </summary>
    </summaries>
    <title>Life-Threatening Diseases Compassion through Combination Therapy Act of 2012</title>
    <titles>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Life-Threatening Diseases Compassion through Combination Therapy Act of 2012</title>
      </item>
      <item>
        <titleType>Display Title</titleType>
        <title>Life-Threatening Diseases Compassion through Combination Therapy Act of 2012</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend title V of the Federal Food, Drug, and Cosmetic Act to provide for extensions of marketing exclusivity periods for drugs in certain combinations of such drugs, and for other purposes.</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2012-09-21T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-112hr6502ih/xml/BILLS-112hr6502ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2012-09-26</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
